Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Medifast, Inc.NYSE: MED
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow turns negative
Q1 FY2026 free cash flow was -$836K, compared with $1.88M a year earlier. Trailing-twelve-month free cash flow was -$1.47M. Over 3 fiscal years it compounded at -80.9% a year.
Context
- Free cash flow amounted to 0.3% of revenue in FY2025, down 2.5 pp from a year earlier.
- Free cash flow increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly free cash flow holds near -$836K or moves back toward the trailing-twelve-month quarterly average of -$367.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 1.25M USD
- Year-over-year change
- -92.7%
- 4-year CAGR
- -62.1%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.25M | -92.7% |
| FY2024 | 2024-12-31 | 17.02M | -87.9% |
| FY2023 | 2023-12-31 | 141.17M | -20.6% |
| FY2022 | 2022-12-31 | 177.89M | +194.8% |
| FY2021 | 2021-12-31 | 60.34M | — |
Free Cash Flow vs competitors
How MED compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -110.9% is the 6th highest of 10, against a peer median of -79.9%.
- Free cash flow amounts to 0.4% of revenue for MED, versus a peer median of 2.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jan 2026 | $19.06M USD | +389.6% | — | 6.6% | |
| FY2025 | HK$14M HKD | -129.1% | — | 3.0% | |
| LTM Mar 2026 | $12.35M USD | -1379.3% | — | 4.9% | |
AIIORobo.ai Inc. | FY2025 | $5.07M USD | -115.2% | -69.6% | 533.3% |
| LTM May 2026 | $4.39M USD | -79.9% | — | 0.4% | |
| LTM Feb 2026 | $3.55M USD | -54.0% | — | 1.1% | |
| LTM Jun 2025 | $2.94M USD | -161.4% | +37.3% | 0.4% | |
| LTM Mar 2026 | $2.43M USD | +91.9% | -52.5% | 2.7% | |
| LTM Mar 2026 | $1.73M USD | -77.8% | -68.5% | 0.3% | |
| LTM Mar 2026 | $1.47M USD | -110.9% | -80.9% | 0.4% | |
| Peer median (excluding MED) | — | -79.9% | -60.5% | 2.7% | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 17.4M | 14.24M |
| Deferred Income Tax | (3.72M) | (924K) | 1.21M | (7.4M) | 11.46M |
| Stock-Based Compensation | 9.9M | 11.05M | 8.19M | 7.36M | 7.64M |
| Change in Working Capital | (87.65M) | 21.65M | 20.28M | (9.75M) | (9.81M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | (126.65M) | 61.19M | 64.27M | 12.17M | 22.19M |
| Accounts Payables | 54.38M | (37.59M) | (35.71M) | (34.99M) | (23.91M) |
| Other Working Capital | 39.01M | (1.94M) | (8.28M) | 13.08M | (8.09M) |
| Other Non-Cash Items | 5.16M | 8.24M | 5.46M | 14.77M | 2M |
| Operating Cash Flow | 94.55M | 194.57M | 147.66M | 24.48M | 6.86M |
| Capital Expenditures | (34.21M) | (16.68M) | (6.48M) | (7.45M) | (5.61M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (54.56M) | (46.6M) | (84.41M) |
| Sales of Investments | 5.15M | 5.27M | 0 | 27.43M | 78.78M |
| Other Investing Activities | 0 | 0 | 0 | 95K | 3.31M |
| Investing Cash Flow | (29.06M) | (11.41M) | (61.05M) | (26.52M) | (7.93M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (62.09M) | (127.96M) | (6.96M) | (836K) | (369K) |
| Dividends Paid | (63.86M) | (71.62M) | (73.02M) | (715K) | (195K) |
| Other Financing Activities | 811K | 0 | 188K | 36K | 0 |
| Financing Cash Flow | (125.13M) | (199.58M) | (79.79M) | (1.52M) | (564K) |
| Effect of Forex Changes | 112K | (67K) | (72K) | 47K | 4K |
| Net Change in Cash | (59.54M) | (16.49M) | 6.75M | (3.51M) | (1.63M) |
| Free Cash Flow | 60.34M | 177.89M | 141.17M | 17.02M | 1.25M |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.